Inspira™ Technologies to Participate in Upcoming Events in May

RA'ANANA, Israel, May 3, 2022 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, today announced that the Company will participate in the following events in May: 

The Medtech Forum 2022                                                      

Format: one-on-one meetings                                   

When: May 3-5

Where: Barcelona International Convention Center, Barcelona, Spain

Who: Dr. Adi Rizansky Nir, VP of Business Development of Inspira Technologies

The 10th EuroELSO Congress 2022                                                    

Format: workshops and one-on-one meetings                                

When: May 4-6

Where: Queen Elizabeth II Centre, London, UK

Who: Dr. Daniella Yeheskely-Hayon, CTO of Inspira Technologies

         Dr. Adi Rizansky Nir, VP of Business Development of Inspira Technologies

         Mr. Tomer Carmeli, Product Manager of Inspira Technologies

Sidoti Virtual Microcap Conference                                                             

Format: Virtual presentation and one-on-one meetings                                     

When: Presentation at 12:15pm ET on May 11

Who: Joe Hayon, president, co-founder & CFO of Inspira Technologies

Benzinga Virtual All Access Show                                                                

Format: Virtual Fireside Chat                                                                          

When: May 20 at 11:00am ET

Who: Joe Hayon, president, co-founder & CFO of Inspira Technologies

Abut Inspira Technologies OXY B.H.N. Ltd.

Inspira Technologies is an innovative medical device company in the respiratory care industry. Inspira Technologies is developing the ART device, a cost effective early extracorporeal respiratory support system with an intent to function as an "Artificial Lung" for deteriorating respiratory patients. The ART device designed to utilize a hemo-protective flow approach aimed to rebalance saturation levels while patients are awake and breathing, potentially minimizing the patient's need for mechanical ventilation. The Company's product has not yet been tested or used in humans and has not been approved by the U.S. Food and Drug Administration (FDA).

For more information, please visit our corporate website: www.inspirao2.com

For more details:

Miri Segal, Investor Relations, MS-IR LLC

+917-607-8654, [email protected]

MRK-ARS-024

Copyright © 2018-2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved.

SOURCE Inspira Technologies

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED